https://doi.org/10.1093/annonc/mdp069
S
Sylvie Lorenzen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
305
Papers
6.2K
Citations
37
h-index
86
i10-index
Sylvie Lorenzen is an academic researcher. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Esophageal Cancer Research and Treatment & Gastrointestinal Tumor Research and Treatment. The author has an h-index of 37, co-authored 260 publications.
Papers by this author
worksCetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
2009 · Annals of Oncology · 241 citations
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
2023 · Journal of Clinical Oncology · 182 citations
https://doi.org/10.1200/jco.23.00975
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
2020 · Annals of Oncology · 111 citations
https://doi.org/10.1016/j.annonc.2019.10.018
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
2024 · Journal of Clinical Oncology · 70 citations
https://doi.org/10.1200/jco.23.02736
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011 · BMC Cancer · 67 citations
https://doi.org/10.1186/1471-2407-11-509
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2015 · European Journal of Cancer · 61 citations
https://doi.org/10.1016/j.ejca.2015.01.059
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat